Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute B cell Lymphoblast leukemia Underwenting Haploidenticl Peripheral blood Stem Cell Transplantation.


Clinical Trial Description

Haploidenticl Peripheral blood Stem Cell Transplantation should be offered to eligible patients with Acute B cell Lymphoblast leukemia whenever feasible. To further improve the outcome of transplantation patients with Acute B cell Lymphoblast leukemia, we developed a modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Chidamide. In this study, we tested the efficacy and feasibility of the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Chidamide in patients with Acute B cell Lymphoblast leukemia undergoing allogeneic peripheral blood stem cell transplantation. ;


Study Design


Related Conditions & MeSH terms

  • Peripheral Blood Stem Cell Transplantation

NCT number NCT05088226
Study type Interventional
Source Chinese PLA General Hospital
Contact Daihong Liu
Phone 86-13681171597
Email daihongrm@163.com
Status Recruiting
Phase Phase 2
Start date December 1, 2021
Completion date June 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04582604 - Ruxolitinib and Decitabine for High Risk Hematological Malignancies Phase 1/Phase 2
Recruiting NCT05436418 - The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation Phase 1/Phase 2
Recruiting NCT05075681 - Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma Phase 1/Phase 2
Completed NCT03993639 - KRN125 for Mobilization of Hematopoietic Stem Cells Phase 2
Completed NCT02398708 - Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT
Completed NCT00575809 - Incidence and Factors Associated With the Development and Severity of Oral Mucositis
Completed NCT00670423 - A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Phase 1
Terminated NCT02326675 - Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant N/A
Recruiting NCT05153226 - GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG Phase 3
Recruiting NCT02848105 - Valproic Acid With Methylprenisonlone for the Treatment of Acute GVHD Phase 2
Not yet recruiting NCT03771222 - Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies Phase 2
Completed NCT02512679 - Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells Phase 2
Recruiting NCT05961410 - Eltrombopag for Peripheral Blood Stem Cell Harvest Phase 2